Lord’s Mark Industries Reports H1 FY27 Profit of ₹82 Crore and Outlines Global Expansion Plans
Lord’s Mark Industries posted strong half-yearly financial results and detailed upcoming commercial rollouts for AI-powered medical devices and cancer treatments across international markets.
- Reported consolidated H1 FY27 PAT of ₹82.01 crore on revenue of ₹718.77 crore.
- Scheduled commercial shipments of AI-based dialysis units to begin in December 2026.
- Initiated regulatory processes to take proprietary CAR-T cancer treatment global.

Photo: Beyond My Ken / Wikimedia Commons (CC BY-SA 4.0)
Lord’s Mark Industries Limited announced its consolidated financial performance for the half year ending September 30, 2026, revealing significant growth in revenue and net income compared to the previous fiscal year. The company recorded a consolidated profit after tax of ₹82.01 crore for the first half of fiscal year 2027, surpassing its total earnings from the entirety of the preceding twelve-month period.
Financial Performance and Revenue Growth
For the half year, consolidated revenue reached ₹718.77 crore, while earnings before interest, taxes, depreciation, and amortization stood at ₹131.51 crore with a margin of 18.30 percent. Profit before tax was reported at ₹112.54 crore, resulting in a basic earnings per share of ₹1.91. Financial indicators demonstrated sequential quarterly improvement, as second-quarter consolidated revenue climbed 34 percent higher than the initial quarter to touch ₹411.09 crore. Second-quarter profit after tax rose by 47 percent to ₹48.83 crore, alongside an operating margin expansion.
On a standalone basis, the enterprise registered revenues of ₹655.31 crore and a net profit of ₹79.56 crore for the same six-month period. Company leadership pointed to broad strategic initiatives and growing manufacturing scale as key drivers behind the accelerated financial momentum, which was reviewed by the Audit Committee and endorsed by the Board of Directors.
Medical Device Production and Technological Milestones
The firm has secured 26 additional in-vitro diagnostics manufacturing licences to broaden its product catalogue. Manufacturing operations for artificial intelligence-based dialysis equipment are underway at the Bengaluru facility, with initial domestic testing successfully concluded. Outright commercial export shipments are scheduled to commence at the end of December 2026, targeting buyers across the United Kingdom, the United States, Africa, Nepal, and Bangladesh.
Additional healthcare offerings are slated for rollout over the subsequent eighteen months, contingent upon regulatory clearances. A formal launch for sickle cell screening products and mass-screening deployments for breast cancer detection devices are scheduled for January 2027. Furthermore, global introductions for practitioner-focused artificial intelligence medical tools and international sales expansion into the British market are planned for early 2027.
Global Therapeutics and Cellular Therapy Strategy
The enterprise has initiated regulatory procedures to introduce its proprietary chimeric antigen receptor T-cell cancer therapy to international jurisdictions including the United States, the United Kingdom, and Europe. Final clinical trials for the cellular therapy are slated to start in February 2027, with formal trial results targeted for publication by December 2027 and advanced treatment facilities projected to become operational by June 2028.
Dr. Sachidanand Upadhyay, Founder, Managing Director, and Chief Executive Officer of Lord’s Mark Industries Limited, stated that the organization aims to establish globally competitive manufacturing foundations and expand its institutional network. The institutional healthcare division currently serves 10,000 customers, including hospitals, with a long-term goal of reaching 25,000 hospitals and laboratories. Concurrently, subsidiary Lord’s Mark Micro Biotech Limited operates over 70 laboratories and collection centres across India, with an anticipated expansion reaching 600 facilities by March 2028.
- Consolidated H1 revenue reached ₹718.77 crore with an EBITDA margin of 18.30 percent.
- The company secured 26 new in-vitro diagnostics manufacturing licences.
- International sales and clinical trials for CAR-T therapies are planned through 2027 and 2028.
Spotted an error? · Our editorial policy
UP NEXTDadasaheb Phalke International Film Festival Awards 2026: Taylor Swift and James Cameron Among WinnersSwipe more stories · BusinessQuick cards, a few lines each. Tap to open.More from Business

Felix Plaza in New Gurugram Expands as a Multi-Utility Retail and Entertainment Hub

Gold Drops to One-Year Low While Silver Falls Sharply Amid US Rate-Rise Expectations and Stronger Dollar

India’s Foreign Exchange Reserves Drop by $14.21 Billion to Three-Month Low
